https://www.selleckchem.com/pr....oducts/Temsirolimus.
79, 95% CI 1.424-5.468 HR 4.544, 95% CI 1.07-19.289, respectively). No significant differences were observed for qHBsAg levels between HCC and non-HCC patients. More than 50% CHB patients on ETV with HBV DNA LLOQ by standard assay had persistent viraemia as determined by a more sensitive assay. Detectable HBV DNA or pgRNA by more sensitive assays was associated with HCC development. More potent viral suppression is required to further reduce the risk of HCC. More than 50% CHB patients on ETV with HBV DNA less then LLOQ
Curtir
Comentario
Compartilhar
